HDAC9 and lymphoma: To date, simultaneous inhibition of phosphoinositide 3-kinase (PI3K) and histone deacetylases (HDACs) is regarded as more effective in the cure for lymphoma or other solid tumors than a single PI3K or HDAC inhibitor [15, 17, 30].